Inactive Instrument
Five Prime Therapeutics, Inc. Share Price
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -4.10% | -8.35% | +38.48% | +66.99% | 66.22B | |
| -0.41% | +3.27% | +10.46% | +73.74% | 55.2B | |
| +0.74% | +4.04% | +12.18% | +91.76% | 52.79B | |
| -0.97% | +1.89% | +26.76% | +50.33% | 45.53B | |
| -1.67% | +1.84% | +21.50% | +125.78% | 43.94B | |
| -3.93% | -1.11% | +253.27% | +919.67% | 41.64B | |
| -1.67% | +8.06% | +14.17% | +56.67% | 34B | |
| -8.38% | -9.01% | +25.65% | -1.82% | 25.84B | |
| +1.30% | +4.94% | +38.23% | +28.03% | 23.51B | |
| Average | -1.87% | +3.43% | +48.97% | +156.79% | 43.19B | |
| Weighted average by Cap. | -1.95% | +3.43% | +47.65% | +159.53% |
Employees
51
